Navigation Links
iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ Technology
Date:4/10/2012

NEWARK, Del., April 10, 2012 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) announced that its proprietary iBioLaunch™ technology for the production of biotherapeutic proteins and vaccine antigens in whole green plants has been used to produce a functional monoclonal antibody copy of palivizumab, a humanized monoclonal antibody that binds to respiratory syncytial virus (RSV) glycoprotein fusion protein (F), and inhibits viral entry into cells. Palivizumab is used to reduce RSV associated hospitalizations, but its high cost limits treatment to high-risk infants who receive monthly intramuscular injections throughout the RSV season. Worldwide annual sales of palivizumab exceed $900 million.

Scientists at iBio's research and development partner, Fraunhofer USA Center for Molecular Biotechnology, have expressed the antibody heavy and light chains in green tissues of plants using an iBioLaunch vector system developed for multi-chain proteins such as antibodies. The expression of palivizumab in plants resulted in self-assembly of the appropriate antibody quaternary structure, which was then recovered from the plant tissue.

iBioLaunch-produced palivizumab was shown to bind inactivated RSV, indicating that it recognizes F antigen presented on the virus' surface. Furthermore, plant-produced palivizumab was demonstrated to have a dose-dependent RSV neutralizing activity in a plaque reduction neutralization test. The effective concentration to observe 50% plaque reduction is comparable for plant-produced palivizumab to that reported for palivizumab manufactured in recombinant mammalian cells. The virus neutralizing activity observed is specific to palivizumab, as demonstrated with the use of an unrelated, plant-produced monoclonal antibody as a negative control for any plant-specific activity.

The production of functional palivizumab in plants extends the n
'/>"/>

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SafeWire, LLC. Announces first US product launch of Y-wire™
2. Sunpeaks Ventures Announces Letter of Intent to Export Clotamin to Top Russian Pharmacies
3. Rapid Fire Marketing Announces the First Shipment of its Vapor Inhaler Model Named the CannaCig Has Passed All Patient Tests; Second Round of Production to Start This Week
4. Sunpeaks Ventures Announces Agreement with Asian American Convenience Store Association Partners to Sell Clotamin in 1,200 Stores
5. Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2012 Results
6. BioNeutral Group Announces Positive Results for the Ygiene 206 Sterilization Tests
7. Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
8. BONESUPPORTS New CEO Announces 100 Day Plan
9. Sunpeaks Ventures Announces Agreement with Albeck Financial Services
10. Psyche Systems Announces Availability of MicroPath, the First LIS for Microbiology
11. Net Medical Xpress Announces 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and CEO of Regulus, will present a ... Jaffray Healthcare Conference at the New York Palace Hotel ... The presentation will be webcast at the time of ...
(Date:11/26/2014)... , Inc. (NASDAQ: BIOS ) announced today that ... at the Bank of America Merrill Lynch 2014 Leveraged Finance Conference ... , Wednesday, December 3, 2014 , , , , Time: ... Location: , , , Boca Raton Resort and Club, Florida , ... BioScrip, Inc. is a leading national provider of infusion and ...
(Date:11/26/2014)... , Nov. 26, 2014 The medical ... a rate of 4%, with world market revenues ... Information. MRI and other types of medical imaging ... treatment of numerous medical conditions in children and ... techniques. Kalorama,s report, Medical Imaging Markets , ...
Breaking Medicine Technology:Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 2Regulus to Present at the 26th Annual Piper Jaffray Healthcare Conference and Genetic Rx Conference 3Kalorama: Steady Growth in the Medical MRI Market 2Kalorama: Steady Growth in the Medical MRI Market 3
... Novelos Therapeutics, Inc. (OTCQX: NVLT) , a pharmaceutical ... of cancer, today announced that the University of ... institution, has successfully completed the first cohort in ... trial of I-124-CLR1404 (LIGHT), a cancer-targeted PET imaging ...
... 2012 HIGHLIGHTS :2012 Results (all ... Q1 2012 reported sales increased 5% to $665 million, a new ... Fine Chemicals ("SAFC") organic sales growth of 4% and 1%, respectively.  ... exchange rates reduced otherwise reportable sales by 2%. , ...
Cached Medicine Technology:Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 2Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 3Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 4Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 2Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 3Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 4Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 5Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 6Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 7Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 8Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 9Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 10Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 11Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 12Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed. 13
(Date:11/28/2014)... Dr. Diane Walder, one of South ... to her practice called Ultrashape that is designed to help ... in just six weeks. Ultrashape has been praised by patients ... results when compared to other types of external fat reduction. ... said Dr. Walder. , According to Dr. Walder, Ultrashape ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... Secura Consultants, based in Minneapolis, ... organizations in the country focused on delivering exemplary ... Secura Consultants is proud to offer complimentary Buy-Sell ... a leading global financial company. , Many businesses ... ownership interest comes the need for business succession ...
(Date:11/28/2014)... News) -- Celebration can quickly turn to tragedy ... experts say. Over the last decade, more than ... people were using turkey fryers, according to the U.S. ... for a patient who tried to deep fry the ... any circumstances," Dr. Arthur Sanford, a burn surgeon at ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter ... involved in the kitchen, through cooking classes or at home, ... to a recent review. Cooking programs and classes for ... according to the new research. And, although the review didn,t ... that such programs might help children develop long-lasting healthy habits. ...
Breaking Medicine News(10 mins):Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Secura Consultants Offers Complimentary Buy-Sell Agreement Reviews 2Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... to determine how gender affects body,s reaction to HIV , ... may explain why HIV infection progresses faster to AIDS in ... say. , Their study found that a receptor molecule involved ... in women than in men. This then leads to differences ...
... , , , ... of St. Jude Children,s Research Hospital, has been invited to give ... , , The Leeuwenhoek Lecture, named ... the field of microbiology. Webster will present the lecture next summer. ...
... AURORA, Ohio, July 13 Arizona Cardinals 2008 NFC ... word to parents that vision problems can interfere with a child,s ... been told your child has perfect vision or 20/20 vision, your ... problem," warns Fitzgerald. , , Do ...
... tolerance to sudden hurts, , MONDAY, July 13 (HealthDay News) ... toe or experiencing some other painful incident? , Your ... , In a study that suggests bad words aren,t all ... hand in ice-cold water were able to withstand the frigid ...
... found that postmenopausal women who have taken a combined ... risk of developing progestin-accelerated breast tumors. Now, University of ... spice derived from the turmeric root, could reduce the ... therapy. "Approximately 6 million women in the United ...
... , , PARAMUS, N.J., July 13 Smart Balance, ... at www.smartbalance.com on August 6, 2009, at 9:30 ... at approximately 8:30 a.m. EDT the same day. The webcast will ... Investors and analysts may participate via conference call by dialing 1-800-895-0198 ...
Cached Medicine News:Health News:Immune Response May Speed AIDS Progression in Women 2Health News:St. Jude Virologist Honored by the Royal Society 2Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 2Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 3Health News:Larry Fitzgerald Offers Advice for Parents With Struggling Readers 4Health News:A Curse or Two Might Quell the Pain 2Health News:A Curse or Two Might Quell the Pain 3Health News:Asian spice could reduce breast cancer risk in women exposed to hormone replacement therapy 2
Anterior Stromal Puncture Cannula, 25 g. For treatment of recurrent corneal erosion. Overall length 24 mm. 5/box....
Viscoelastic Cannula, 23 g. Angled. 7 mm angled tip cannula with unique hub that facilitates flow of viscoelastic material. Overall length 23 mm. 5/box....
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Anterior Chamber Needle, 25 g. Angled. 9 mm angled tip. Overall length 19 mm. 5/box....
Medicine Products: